Related Experiment Videos
Immunoglobulin prophylaxis for infants exposed to varicella in a neonatal unit
G Patou1, P Midgley, E V Meurisse
1Department of Medical Microbiology, University College Hospital, London, U.K.
Insights
Anti-varicella-zoster immunoglobulin (ZIG) may not be necessary for all preterm infants exposed to varicella-zoster virus (VZV). Findings suggest ZIG is primarily needed for seronegative infants or those born to seronegative mothers, and over 60 days old.
Area of Science:
- Neonatal Medicine
- Immunology
- Infectious Diseases
Background:
- Preterm infants are vulnerable to severe outcomes following varicella-zoster virus (VZV) exposure.
- Current guidelines recommend anti-varicella-zoster immunoglobulin (ZIG) for VZV-exposed preterm infants under 28 weeks gestation.
Purpose of the Study:
- To investigate the necessity and efficacy of ZIG prophylaxis in preterm infants exposed to VZV.
- To refine current recommendations for ZIG administration in this vulnerable population.
Main Methods:
- Retrospective analysis of 15 preterm infants (24-33 weeks gestation) exposed to VZV in a neonatal intensive care unit.
- Assessment of VZV IgG antibody status in infants and maternal seropositivity.
- Evaluation of ZIG administration based on gestational age, postnatal age, and serological status.
Main Results:
- VZV IgG was detected in 13 infants (24-28 weeks gestation) born to seropositive mothers, indicating passive immunity.
- The study suggests ZIG may be overutilized in certain preterm infant populations.
- Identified specific criteria for ZIG administration, including seronegativity and postnatal age.
Conclusions:
- ZIG prophylaxis may be selectively administered to preterm infants based on their VZV serological status and maternal immunity.
- Findings challenge the blanket recommendation of ZIG for all VZV-exposed preterm infants under 28 weeks gestation.
- Recommendations for ZIG use should consider infant seronegativity and postnatal age (over 60 days).
Abstract:
The investigation and prophylaxis with anti-varicella-zoster immunoglobulin (ZIG) of 15 preterm infants (24-33 weeks gestation and 1-300 days postnatal age) exposed to varicella on a neonatal intensive care unit are described. Varicella-zoster virus (VZV) IgG was detectable in 13 infants (24-28 weeks gestation) less than 105 days of age and born to seropositive mothers. Current guidelines recommend ZIG for all preterm infants of less than 28 weeks gestation following exposure to VZV. Our findings suggest that ZIG need be given only to seronegative infants or infants of seronegative mothers and to those over 60 days postnatal age.